‘This works’: Rebyota safe, effective when given by colonoscopy for recurrent C. difficile (Healio)

At DDW 2025, results from the CDI-SCOPE trial showed that 95% of adults with recurrent Clostridioides difficile infection achieved treatment success 8 weeks after receiving Rebyota (fecal microbiota, live-jslm) via colonoscopy. The trial confirmed Rebyota’s safety profile, with only mild GI-related side effects reported. Physicians also found the administration process efficient and positive. These findings support colonoscopy as a viable and effective delivery method for microbiota restoration therapy in rCDI patients.